Darzalex | Janssen Medical Cloud

Indications for DARZALEX^®^[1]

DARZALEX^® for multiple myeloma

Frontline transplant-eligible

.gbi-4182015-dibL7ioyN8Ro7mexBTARHZ:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/bltca5ac1306ff28f7b/61b9c7ac6acea72b12eee8e8/replace_me_blue.png?width=423&height=118&format=png&quality=50''); }

Frontline transplant-ineligible

.gbi-4182015-poexCbmUWHdXfxUJDmvh91:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/bltca5ac1306ff28f7b/61b9c7ac6acea72b12eee8e8/replace_me_blue.png?width=423&height=118&format=png&quality=50''); }

.gbi-4182015-nuG43zaypk1PKzVxXB3v3h:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/bltca5ac1306ff28f7b/61b9c7ac6acea72b12eee8e8/replace_me_blue.png?width=423&height=118&format=png&quality=50''); }

From 2nd line

.gbi--1756384746-tS61rM8xL5xvoiEvbQWrHN:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/blt7771ad0e62eae49b/61b9c97a8c873b37a7c6f47f/replace_me_pink.png?width=423&height=118&format=png&quality=50''); }

.gbi--1756384746-dEaJ4E2nSf3DyNdXe3Dkgc:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/blt7771ad0e62eae49b/61b9c97a8c873b37a7c6f47f/replace_me_pink.png?width=423&height=118&format=png&quality=50''); }

From 3rd line

.gbi-1440090518-oKNNQLJzRHTDXNxncxJsHA:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/blt955cef244eaac167/61b9cb7ce661952b180feb47/replace_me_grey.png?width=1300&height=118&format=png&quality=50''); }

DARZALEX^® for AL amyloidosis

Newly-diagnosed

.gbi-1440090518-42NxqEbW3gaQrQqGFkCCNu:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/blt955cef244eaac167/61b9cb7ce661952b180feb47/replace_me_grey.png?width=1300&height=118&format=png&quality=50''); }

DARZALEX^® practical guides

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex^® SC.

Darzalex^® SC Practical Guide

Includes DARZALEX^® SC handling and administration info, pre and post-injection medications, and more

Dosing schedules for all Darzalex^® treatment regimens

Find more about DARZALEX^® and multiple myeloma

Prof. Mateos presents 4-year updates of POLLUX study

María-Victoria Mateos of Hospital Universitario de Salamanca

21 February 2020 ASH 2019

Prof. Mateos presents 4-year updates of CASTOR study

María-Victoria Mateos of Hospital Universitario de Salamanca

21 February 2020 ASH 2019

ALCYONE update

Prof. María-Victoria Mateos presents 1-year updates from ALCYONE

DARZALEX^® SC practical guidance

DARZALEX^® SC preparation

An interactive video covering the key facts about the handling, preparation and administration of DARZALEX^® SC

DARZALEX^® SC studies

DARZALEX^® SC STUDIES

In this interactive video, Prof. Mateos gives an overview of the DARZALEX^® SC PAVO, COLUMBA and PLEIADES studies.

Patient materials

Supporting patients on their journey

Access downloadable patient materials to help your patients and their caregivers on their journey with MM treatment

.gbi-1413266763-tJf1vzcXbJ2G5r9uJc9Mc3:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt193a365f63e4aaa2/blt6e927761db92d67d/61b9d9c71f28621fdd7ab19e/replace_me_MWO.png?width=1364&height=256&format=png&quality=50''); }

DARZALEX^® is the first approved CD38‑targeting immunotherapy for multiple myeloma (MM)^[2]

Glossary

AL: amyloid light chain

IRR: infusion-related reaction

MM: multiple myeloma

MOA: mode of action

Rd: lenalidomide, dexamethasone

SC: subcutaneous

VCd: Velcade^®, cyclophosphamide, dexamethasone

Vd: Velcade^®, dexamethasone

VMP: Velcade^®, melphalan, prednisone

VTd: Velcade^®, thalidomide, dexamethasone

Para visualizar o IECRCM de Darzalex, veja aqui.

Referências

[1]

RCM DARZALEX ^®. Acedido em março de 2022. Disponível em www.ema.europa.eu

[2]

Sanchez, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. Journal of Hematology & Oncology. 2016; 9:51.

CP-287814 - March 2022

Indications for DARZALEX®[1]

DARZALEX® for multiple myeloma